Comparing Myval Balloon-Expandable Valve and Surgical Valve Replacement for Severe Aortic Stenosis in Patients Aged 65 to 75
Led by Ceric Sàrl · Updated on 2026-05-12
1180
Participants Needed
49
Research Sites
469 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare the clinical outcomes of the Myval balloon-expandable transcatheter heart valve THV series with those of surgical bioprosthetic aortic valve replacement SAVR in patients aged 65 to 75 years who have symptomatic severe aortic stenosis. The study is a prospective, randomized, multinational, multicenter, open-label trial including 1180 participants. It assesses whether the Myval THV is not worse than SAVR regarding safety and effectiveness.
Participants are randomly assigned to receive either the Myval balloon-expandable THV or a surgical bioprosthetic valve available at the clinical site. The procedures involve either transcatheter aortic valve replacement TAVR using the Myval device or standard surgical aortic valve replacement SAVR. The study includes a CT scan sub-study at selected sites to evaluate the feasibility of valve re-interventions and valve performance.
During the study, participants will be monitored for safety and efficacy outcomes including death, stroke, bleeding, kidney injury, rehospitalization, and valve function over periods ranging from 1 month to up to 10 years. Assessments include clinical evaluations, transthoracic echocardiograms, CT scans, and recording of adverse events. The research team will track valve hemodynamics, complications, and the need for interventions to understand long-term results and safety.
CONDITIONS
Brief Title
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
Research Team
P
Philippe Garot, MD
M
Marie-Claude Morrice, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Symptomatic severe aortic stenosis with mean gradient ≥40 mmHg and/or peak velocity >4 m/sec
Symptomatic heart disease due to severe native calcific aortic stenosis
Eligibility for SAVR or transfemoral TAVR approved by multidisciplinary heart team
Signed informed consent for participation
You will not qualify if you...
Unable to understand or follow study instructions or comply with protocol
Life expectancy less than 1 year
Known allergy to aspirin, clopidogrel, or device frame components
Under judicial protection, tutorship, or curatorship
Participation in another trial before the primary endpoint
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Hospital stay duration as determined by clinical care
Participants undergo either surgical bioprosthetic aortic valve replacement or transcatheter aortic valve replacement (TAVR) followed by immediate post-operative care.
1 procedure visit and immediate post-operative hospital stay
Post-operative Follow-up
Duration - Up to 10 years
Participants are monitored for safety and efficacy including assessments of valve performance and health status following the procedure.
Multiple follow-up visits at 1 month, 1 year, and annually up to 10 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Methodological Appraisal of Ongoing Trial of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Younger Patients: From Incentives to Guideline-Informing Evidence.